éå»1ã¶æéã«Aclaris Therapeutics Incã«å¯ŸããŠè©äŸ¡ãåºããã¢ããªã¹ã12åã«åºã¥ãããŒã¿ã
仿ãACRSã¯5ä»¶ã®ãè²·ããã1ä»¶ã®ãäžç«ïŒããŒã«ãïŒãã0ä»¶ã®ã売ããè©äŸ¡ãç²åŸããŸãããçŽè¿1ã¶æã«ãããACRSã®ã¢ããªã¹ãå¹³åç®æšæ ªäŸ¡ã¯9.958ã§ãã
ã¢ããªã¹ãäºæ³ã«ãããšãFY2026Q2ã«çºè¡šãããEPS -0.151ã«ç¶ããACRSã®FY2026Q3ã®EPSã¯-0.165ã«éããèŠéãã§ããçºè¡šãããå®çžŸå€ãšäºæ³ãæ¯èŒããŠãåçæ§ã®æšç§»ã確èªããŸãããã
åžå Žäºæ³ã¯ USD -0.15 ã§ããããAclaris Therapeutics IncACRS ã®åååæã®äžæ ªåœããå©ç (EPS) 㯠USD -0.15 ã§ãããæ¬¡ã®ååæã® EPS 㯠USD -0.16 ãšäºæ³ãããŸãã